Abstract
The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.
Original language | English (US) |
---|---|
Pages (from-to) | 277-285 |
Number of pages | 9 |
Journal | Hematology (United States) |
Volume | 2018 |
Issue number | 1 |
DOIs | |
State | Published - Nov 30 2018 |
ASJC Scopus subject areas
- Hematology